Anne-marie M. Stoppa
Marseille, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
Journal: European journal of haematology
Published: February 13, 2023
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
Journal: British journal of haematology
Published: November 20, 2022
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Journal: Haematologica
Published: October 14, 2022
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Journal: Haematologica
Published: December 22, 2021
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 11, 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 26, 2021
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods.
Journal: Leukemia
Published: July 03, 2020
Last Updated: 09/26/2026